ClinicalTrials.gg
CompletedNCT03374800REVISEUpdated Sep 20, 2024

Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial

A Phase 3 interventional study of Placebo (0.9% saline) and Pantoprazole in Gastrointestinal Hemorrhage (Clinically Important, Upper), sponsored by McMaster University. Completed at 67 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-20.

Sponsored by McMaster University · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was Oct 2023, 3 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies in Gastrointestinal Hemorrhage with a site in Canada — 4 open to participants now, 5 under way, 1 of them phase 3. Gastrointestinal Hemorrhage · Canada.

Enrollment
2nd of 14
4,800 · median 113
Started
2018
with 1 other
Phase 3
5 of 18
1 open now
Registered
9th of 18
by date
Lead sponsor
4 of 18
McMaster University

Among the 18 studies in Gastrointestinal Hemorrhage with a site in Canada, this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2018, is one of 5 in phase 3, and was the 9th registered.

Gastrointestinal Hemorrhage

338 studies on the registry are indexed under Gastrointestinal Hemorrhage; 77 are open to participants now.

Browse Gastrointestinal Hemorrhage studies →

Open to participants now

4 of the 18 studies in Gastrointestinal Hemorrhage with a site in Canada are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 49 Gastrointestinal Hemorrhage studies recruiting now, 39 (80%) set no upper age limit and 4 (8%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Gastrointestinal Hemorrhage with a site in Canada, or all of them as a file.
02

Study summary

Patients who are critically ill in the in the Intensive Care Unit (ICU), especially those who need a breathing machine, can develop ulcers in the stomach that bleed. To prevent bleeding, many such patients around the world receive a drug called pantoprazole that decreases acid production. However, today, compared to decades ago, critically ill patients rarely develop upper gastrointestinal bleeding. This decrease is likely due to modern medicine, better resuscitation and earlier feeding. There may also be harms associated with pantoprazole and other drugs that reduce acid levels in the stomach including lung infections (pneumonia) and bowel infections (Clostridioides difficile). Studies in this area are old and of modest quality. Therefore, it is difficult to know whether pantoprazole does decrease stomach bleeding these days, or whether the possible harms of lung and bowel infections are actually more common and more serious problems. The goal of this international study is to determine if, in critically ill patients using breathing machines, the use of pantoprazole is effective in preventing bleeding from stomach ulcers or whether it causes more problems such as lung infection (pneumonia) and bowel infection (Clostridioides difficile), or whether pantoprazole has no effect at all. Whether the harms are worth the benefits, and whether the benefits are worth the costs, will be determined by an economic analysis to inform patients, families, clinicians, and healthcare systems globally.

Read the detailed description

Background: For 40 years, pharmacologic prevention of stress ulcer-related gastrointestinal (GI) bleeding with acid suppression has been the standard of care for invasively mechanically ventilated ICU patients. Worldwide, proton pump inhibitors (PPIs) are more commonly used than histamine-2-receptor antagonists. Observational studies and the latest network meta-analysis suggest that PPIs increase the risk of ventilator-associated pneumonia (VAP) and Clostridioides difficile infection (CDI). However, a recent large randomized trial showed that pantoprazole had no impact on the primary outcome of 90-day mortality. The secondary outcome (a composite of pneumonia, gastrointestinal bleeding, CDI and acute myocardial ischemia) was not different between the groups. Although pantoprazole was associated with a significantly lower rate of clinically important upper GI bleeding, some bleeding events required no blood transfusion, endoscopy or other diagnostic or therapeutic interventions, calling into question whether these bleeding events were truly patient-important. Further, patients with high illness severity on pantoprazole had a significant, unexplainable higher risk of death than those receiving placebo.

REVISE Pilot Trial: We completed the 91-patient REVISE Pilot Trial in Canada, Australia and Saudi Arabia, demonstrating a high consent rate (77.8%); recruitment rate (2.6 patients/month/center); and protocol adherence (96.8%), thereby successfully establishing the feasibility of a larger REVISE Trial.

Objectives of the REVISE Trial: To determine, among invasively mechanically ventilated patients, the effect of pantoprazole versus placebo on the primary efficacy outcome of clinically important upper GI bleeding, and the primary safety outcome of 90-day mortality. Secondary outcomes are VAP, CDI, acute kidney injury, ICU mortality, hospital mortality and patient-important upper GI bleeding. Tertiary outcomes are transfused packed red blood cells, serum creatinine, duration of mechanical ventilation, duration of ICU stay and duration of hospital stay.

Methods: We will include 4,800 ICU patients >18 years old who have an anticipated duration of mechanical ventilation of ≥48 hours. Exclusion criteria are acute or recent GI bleeding, dual antiplatelet therapy, combined antiplatelet and anticoagulant therapy, hopeless prognosis or intent to withdraw advanced life support, and previous enrolment in this or a confounding trial. Patients will be randomized in a fixed 1:1 allocation, stratified by center and pre-ICU acid suppression ('start or no start' strata, and 'continue or discontinue' strata). Research Coordinators will obtain informed consent using a deferred or a priori consent model. Study Pharmacists will obtain concealed allocation from the REVISE website; all research team and clinical team members, patients and families will be blinded. Patients will receive pantoprazole 40 mg or identical placebo intravenously daily while in ICU up to 90 days or until: 1) successful discontinuation of mechanical ventilation for >48 hours; 2) development of clinically important upper GI bleeding, or 3) death in ICU. Analyses will be by intention-to-treat with a sensitivity analysis restricted to patients receiving study drug on ≥ 80% of study days while mechanically ventilated per protocol.

Collaborations: REVISE will be conducted in collaboration with the Canadian Critical Care Trials Group, the Australian and New Zealand Critical Care Trials Group, other consortia and interested international investigators.

Ethical Imperative: Many factors converge to underscore the ethical imperative for REVISE. Critical care has evolved, research standards have improved, epidemiology may have changed, the risk:benefit and cost:benefit ratios of prophylaxis may have shifted. Thus, stress ulcer prophylaxis may need to be REVISED.

Relevance: Most invasively mechanically ventilated patients around the world receive daily stress ulcer prophylaxis, although variation exists such that some centers do not use any. Many RCTs of stress ulcer prophylaxis were conducted 10-30 years ago, several are at moderate or high risk of bias, and cointerventions may not reflect current critical care. A recent large trial raised concerns about death associated with pantoprazole in the most severely ill patient subgroup. Although clinically important upper GI bleeding events were less frequent, they may not have been patient-important, and there were no other benefits observed. Consensus in the scientific and clinical community is that equipoise remains regarding whether routine use of pantoprazole should continue for stress ulcer prophylaxis during critical illness. The question is especially important for patients who are receiving acid suppression pre-ICU, those who are receiving enteral nutrition, and those at high risk of death. Today, infectious complications of PPIs have emerged as potentially more common and serious than upper GI bleeding. The number needed to prophylax to prevent 1 GI bleed and the cost per GI bleed averted may be very high; furthermore, the number needed to harm to cause 1 episode of VAP or CDI may be low. Recent practice guidelines are conflicting. Remaining doubts about the effectiveness and safety of PPIs urge re-examination of universal prophylaxis for possible de-adoption. Aligned with the 'Choosing Wisely' Campaign, REVISE and the companion economic evaluation (E-REVISE) will be incorporated into guidelines to inform global practice.

03

Conditions studied

  • Gastrointestinal Hemorrhage (Clinically Important, Upper)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or more.
  2. Receiving invasive mechanical ventilation in an ICU and in the opinion of the treating ICU physician mechanical ventilation will not be discontinued before the end of the day after tomorrow.

Exclusion criteria

Exclusion Criteria:

  1. The treating clinician considers either Pantoprazole or placebo are indicated or for this patient.
  2. Pantoprazole contraindicated for patient due to local product information;

    Australia/New Zealand;

    • being treated with protease inhibitors atazanavir or nelfinavir
    • being treated with high dose methotrexate (i.e., greater than 300 mg as part of a chemotherapy regimen).
    • documented cirrhosis or severe liver disease (for example as indicated by an greater than 5.0 due to underlying liver disease).

    Canada;

    • being treated with rilpivirine or atazanavir
    • patients who are hypersensitive to pantoprazole, substituted benzimidazoles, or to any ingredient in the formulation
  3. Patients in whom a PPI or histamine 2 receptor antagonist (H2RA) is indicated due to active bleeding or increased bleeding risk, defined as patients with acute GI bleeding, severe oesophagitis or peptic ulcer disease within the previous 8 weeks, Zollinger Ellison syndrome, Barrett's oesophagus or any previous admission to hospital because of upper GI bleeding (patients receiving PPIs for mild dyspepsia or mild gastroesophageal reflux disease or an uncertain indication are not excluded).
  4. Received invasive mechanical ventilation during this ICU admission for 72 hours or more.
  5. Patients who have received more than 24 hours treatment (i.e., more than one daily dose equivalent) with a PPI or H2RA during this ICU admission.
  6. Being treated with or need for dual anti- therapy.
  7. Admitted for palliative care or the ICU physician is not committed to continuing life-sustaining therapies at the time of enrolment.
  8. Known or suspected pregnancy.
  9. Physician, patient, or substitute decision maker (SDM) declines.
  10. Previously enrolled in the REVISE trial
  11. Enrolled in another trial for which co-enrolment is not approved.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4,800 participants (actual)

Study arms

  • Placebo comparator
    Placebo (0.9% saline)

    Withholding Stress ulcer prophylaxis (intravenous 0.9% saline as placebo)

    Drug: Placebo (0.9% saline)

  • Active comparator
    Stress Ulcer Prophylaxis (Pantoprazole)

    pantoprazole 40mg powder for injection reconstituted with 0.9% saline

    Drug: Pantoprazole

Interventions

  • DrugPlacebo (0.9% saline)

    normal saline

    Also known as: normal saline; NaCl 0.9%

  • 40 mg powder for injection reconstituted with 0.9% saline

    Also known as: Protonix

06

What researchers measure

Primary outcomes

  1. Rate of clinically important upper gastro-intestinal bleeding

    Clinically important upper GI bleeding requires the presence of overt GI bleeding which is defined as one of the following; * Hematemesis * Overt nasogastric bleeding * Melena * Hematochezia PLUS (in the absence of another cause), at least one of the following in the 24 hours following overt GI bleeding: * Haemodynamic change defined as a spontaneous decrease in invasively monitored mean arterial pressure or non-invasive systolic or diastolic blood pressure of 20 mmHg or more or an orthostatic increase in pulse rate of 20 beats/minute and a decrease in systolic blood pressure of 10 mmHg, with or without vasopressor initiation, or increase * Vasopressor initiation * A decrease in haemoglobin of ≥ 20 g/l in a 24-hour period or less, * Transfusion of ≥2 units of packed red blood cells within 24 hours of bleeding to maintain stable haemoglobin or haemodynamics, or * Need for therapeutic intervention (e.g. angiography, surgery or endoscopic treatment of bleeding).

    Time frame: 90 days (In ICU or resulting in ICU readmission, censored at 90 days after randomization)

  2. Primary Safety Outcome: 90 Day Mortality

    Mortality status at day 90 post randomization

    Time frame: 90 days post randomization

Secondary outcomes

  1. Rate of ventilator associated pneumonia (VAP) in ICU

    Diagnostic criteria for VAP include: previous mechanical ventilation for at least 48 hours, a new, progressive or persistent radiographic infiltrate on chest X-ray (without other obvious cause) plus at least 2 of the following 4 features: * fever or hypothermia (temperature \>38 °C or \<36 °C) * relative leukopenia or leukocytosis (WBC\<4.0 or \>12 x 10\^9/L) * purulent sputum * gas exchange deterioration Using these uploaded data, the Clinical Pulmonary Infection Score is calculated. A score of 6 or greater is the primary definition of ventilator-associated pneumonia

    Time frame: 90 Days (while in ICU,censored at 90 days after randomization)

  2. Rate of Clostridioides difficile associated infection

    We will use clinical features (diarrhea, ileus, toxic megacolon) and either microbiological evidence of toxin producing Clostridioides difficile or Pseudomembranous colitis on colonoscopy.

    Time frame: 90 days (during the index hospital admission, censored at 90 days)

  3. New initiation of treatment with renal replacement therapy in ICU

    Rate of New initiation of treatment with renal replacement therapy in ICU

    Time frame: 90 Days (In the ICU, censored at 90 days)

  4. Rate of all-cause-in-hospital mortality

    hospital mortality

    Time frame: While in hospital, censored at 90 days after randomization

  5. Rate of ICU mortality

    ICU mortality

    Time frame: While in the ICU, censored at 90 days after randomization

  6. Rate of patient important upper GI bleeding in ICU or resulting in ICU readmission, censored at 90 days after randomization

    Patient important upper GI bleeding in ICU or resulting in ICU readmission, censored at 90 days after randomization

    Time frame: Censored at 90 days after randomization

Other outcomes

  1. Total units of red blood cells transfused in the first 14 days of ICU stay

    Total units of red blood cells transfused in the ICU in the first 14 days

    Time frame: Censored at 14 days after randomization

  2. Peak serum creatinine concentration in ICU

    Peak serum creatinine concentration in ICU

    Time frame: Censored at 90 days after randomisation

  3. Duration of mechanical ventilation (days)

    Duration of mechanical ventilation (days)

    Time frame: Censored at 90 days after randomisation

  4. ICU length of stay (days)

    ICU length of stay (days)

    Time frame: Censored at 90 days after randomisation

  5. Hospital length of stay (days)

    Hospital length of stay (days)

    Time frame: Censored at 90 days after randomisation

07

Study locations

67 sites
  • University of Nebraska - Nebraska Medical Center
    Omaha, Nebraska 987400, United States
  • Bankstown-Lidcombe Hospital
    Bankstown, New South Wales 2200, Australia
  • Blacktown Hospital
    Blacktown, New South Wales 2148, Australia
  • Sutherland Hospital
    Caringbah, New South Wales 2050, Australia
  • Gosford Hospital
    Gosford, New South Wales 2250, Australia
  • Nepean Hospital
    Kingswood, New South Wales 2747, Australia
  • St George Hospital
    Kogarah, New South Wales 2217, Australia
  • Royal North Shore Hospital
    Saint Leonards, New South Wales 2050, Australia
  • Wollongong Hospital
    Wollongong, New South Wales 2500, Australia
  • Royal Brisbane Womens Hospital
    Brisbane, Queensland 4029, Australia
  • Ipswich Hospital
    Ipswich, Queensland 4305, Australia
  • Mater Hospital
    South Brisbane, Queensland 4101, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Bendigo Health
    Bendigo, Victoria 3550, Australia
  • Geelong University Hospital
    Geelong, Victoria 3220, Australia
  • Austin Hospital
    Heidelberg, Victoria 3084, Australia
  • Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Royal Melbourne Hospital
    Melbourne, Victoria 3050, Australia
  • Epworth Hospital
    Melbourne, Victoria 3121, Australia
  • Sociedade Hospitalar Angelina Caron
    Campina Grande Do Sul, Brazil
  • Beneficência Social Bom Samaritano
    Governador Valadares, 35044-220, Brazil
  • Foothills Hospital
    Calgary, Alberta, Canada
  • Peter Lougheed Hospital
    Calgary, Alberta, Canada
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • Nanaimo Regional General Hospital
    Nanaimo, British Columbia V9S 2B7, Canada
  • Royal Columbian Hospital
    New Westminster, British Columbia V3L 3W7, Canada
  • Vancouver General Hospital
    Vancouver, British Columbia, Canada
  • Vancouver Island Health Authority
    Victoria, British Columbia, Canada
  • St. Boniface Hospital
    Winnipeg, Manitoba R2H 2A6, Canada
  • Health Science Center Winnipeg
    Winnipeg, Manitoba R3A 1R9, Canada
  • Grace Hospital
    Winnipeg, Manitoba R3J 3M7, Canada
  • Saint John Regional Hospital
    Saint John, New Brunswick E2L 4L2, Canada
  • QEII Health Sciences Centre
    Halifax, Nova Scotia B3H 2Y9, Canada
  • William Osler Hospital, McKenzie Health, Brampton Civic Hospital
    Brampton, Ontario L6R 3J7, Canada
  • Brantford General Hospital
    Brantford, Ontario, Canada
  • Cambridge Memorial Hospital
    Cambridge, Ontario N1R 3G2, Canada
  • St. Joseph's Healthcare Hamilton
    Hamilton, Ontario L9N 4A6, Canada
  • Hamilton Health Science Center - General Hospital
    Hamilton, Ontario, Canada
  • Hamilton Health Science Center - Juravinski Hospital
    Hamilton, Ontario, Canada
  • Kingston General Hospital
    Kingston, Ontario, Canada
  • Grand River Hospital
    Kitchener, Ontario N2G 1G3, Canada
  • London Health Science Center (LHSC) - University Hospital
    London, Ontario, Canada
  • London Health Science Center (LHSC) - Victoria Hospital
    London, Ontario, Canada
  • North York General Hospital
    North York, Ontario M2K 1E1, Canada
  • Ottawa Health Research Institute - OHRI (General and Civic Hospital)
    Ottawa, Ontario, Canada
  • Niagara Health Services - St. Catharine's Hospital
    St. Catharines, Ontario, Canada
  • Sunnybrook Health Science Center
    Toronto, Ontario M4N 3M5, Canada
  • Mount Sinai Hospital
    Toronto, Ontario M5G 1X5, Canada
  • University Health Network - Toronto Western Hospital
    Toronto, Ontario M5T 2S8, Canada
  • St. Joseph's Health Centre, Toronto
    Toronto, Ontario M6R 1B5, Canada
  • St. Michael's Hospital
    Toronto, Ontario, Canada
  • Windsor Regional Hospital
    Windsor, Ontario N8W 1L9, Canada
  • Centre de recherche de l'Hôtel-Dieu de Lévis
    Lévis, Quebec, Canada
  • Hôpital Maisonneuve Rosemont
    Montréal, Quebec H1T 2M4, Canada
  • Center Hospital University Montreal (CHUM)
    Montréal, Quebec H2X 0A9, Canada
  • Centre Universitaire de Santé McGill / McGill University Health Centre
    Montréal, Quebec, Canada
  • CIUSS du Nord de l'île de Montréal - Hôpital du Sacré-Cœur de Montréal
    Montréal, Quebec, Canada
  • McGill University Health Centre - Montreal General Hospital
    Montréal, Quebec, Canada
  • CHU de Québec-Université Laval - Hôpital Enfant-Jésus
    Quebec City, Quebec, Canada
  • Institut Universitaire de cardiologie et de pneumologie de Québec Laval, Quebec
    Quebec City, Quebec, Canada
  • Centre Hospitalier Universitaire de Sherbrooke
    Sherbrooke, Quebec J1H 5N4, Canada
  • Regina General Hospital
    Regina, Saskatchewan S4P 0W5, Canada
  • AL-Amiri Hospital
    Kuwait City, Kuwait
  • Maroof International Hospital
    Islamabad, Pakistan
  • King Abdulaziz Medical Center
    Riyadh, 11426, Saudi Arabia
  • Guys & St. Thomas Hospital
    London, New Westminster SE1 7EH, United Kingdom
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Following the publication of REVISE, the dataset will be used for secondary observational studies addressing additional hypothesis-driven questions (e.g., predictors of gastrointestinal bleeding). Access by REVISE investigators will follow a submitted rationale, analysis plan and approval by the Management Committee. Requests for access to the dataset by external academic investigators will be considered following a submitted rationale, analysis plan and approval by the Management Committee and research ethics boards as relevant. Only de-identified data will be provided and will be transferred via a secure web portal. Requirements will be stipulated in a pre-specified data sharing agreement with investigators which aligns with each institution including the data sharing policy of The George Institute (https://www.georgeinstitute.org.au/data-sharing-policy.)

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anticipated availability 2025 for up to 15 years.

Access criteria: Following the publication of REVISE, the dataset will be used for secondary observational studies addressing additional hypothesis-driven questions (e.g., predictors of gastrointestinal bleeding). Access by REVISE investigators will follow a submitted rationale, analysis plan and approval by the Management Committee. Requests for access to the dataset by external academic investigators will be considered following a submitted rationale, analysis plan and approval by the Management Committee and research ethics boards as relevant. Only de-identified data will be provided and will be transferred via a secure web portal. Requirements will be stipulated in a pre-specified data sharing agreement with investigators which aligns with each institution including the data sharing policy of The George Institute (https://www.georgeinstitute.org.au/data-sharing-policy.)

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Oct 2023, 63 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2017
First posted
Dec 15, 2017
StartActual
Jul 9, 2018
Primary completionActual
Oct 31, 2023
CompletionActual
Jan 31, 2024
Last update
Sep 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03374800
Collaborators
Canadian Institutes of Health Research (CIHR), Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group, National Health and Medical Research Council, Australia
Responsible party
Sponsor
First posted
Dec 15, 2017
Start date
Jul 9, 2018
Primary completion
Oct 31, 2023
Completion
Jan 31, 2024
Last update
Sep 20, 2024

Study contacts

Deborah Cook, MD
principal investigator · McMaster University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pantoprazole

Start the discussion